EGFR and colorectal carcinoma: However, there were numerically fewer patients with presumed RAS-wild type CRC or anti-EGFR antibody use in the previous line of therapy, and numerically more patients with a bevacizumab, irinotecan, or FOLFOXIRI (leucovorin, 5-FU, oxaliplatin, irinotecan) prescription, in the ramucirumab and aflibercept beta groups than in the bevacizumab group.